Upstream Bio, Inc.(UPB) - 2025 Q1 - Quarterly Results

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs – Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dose ...